EUVIMEDEUVIMED entdecken
Open Access

Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8 + T cell exhaustion-suppressed antitumor immunity

Guolong Liu iD, Xiaoling Tian iD, Qiudao Wang, Saijuan Xu, Yanhong Jiang, Ying Gao, Yuxuan Wu iD

Science Advances · 15.08.2025 · 11 (33)

DOI: 10.1126/sciadv.adx9221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 15.08.2025. Verfasst von Guolong Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Epigenesis, Genetic, Neoplasms, Transcription Factors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD8 + T play essential roles in antitumor immune responses. However, immunotherapy has limited clinical efficacy in many solid tumors. Here, we performed an epigenetic-wide CRISPR-Cas9 screen in CD8 + T cells directly under cancer immunotherapy setting and found that Prdm12 is a transcriptional repressor implicated in nociceptive neuron development but uncharacterized within immunological contexts. Prdm12 deletion markedly enhanced in vivo tumor clearance of mouse CD8 + T cells and promoted activation, effector differentiation marker expression, and cytokine secretion in both murine and human CD8 + T cells in vitro. Mechanistically, Prdm12 deficiency augmented effector transcriptional programs while inhibiting exhaustion of CGRP-RAMP1 neuroimmune axis facilitation. Additionally, Prdm12 ablation remodeled the chromatin accessibility landscape, with H3K9me3 deposition at loci regulating T cell differentiation ( Trib1 and Sgk1 ) and exhaustion ( Rgs1 and Nr4a2 ). These results together reveal a negative regulatory mechanism for CD8 + T cells and advance our understanding of cancer immunotherapy by linking neurobiological signaling to immune regulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesEpigenesis, GeneticNeoplasmsTranscription FactorsAnimalsMiceHumansImmunotherapyT-Cell Exhaustion

Substanzen

Transcription Factors

Autor:innen und Institutionen

  • Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 2…
  • YolTech Therapeutics, Shanghai 201199, China.

ORCID-Profile: Guolong Liu, Xiaoling Tian, Yuxuan Wu

Zitieren

APA

Liu, G., Tian, X., Wang, Q., Xu, S., Jiang, Y., Gao, Y., & Wu, Y. (2025). Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8 + T cell exhaustion-suppressed antitumor immunity. Science Advances, 11(33). https://doi.org/10.1126/sciadv.adx9221

Vancouver

Liu G, Tian X, Wang Q, Xu S, Jiang Y, Gao Y, et al. Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8 + T cell exhaustion-suppressed antitumor immunity. Science Advances. 2025;11(33). doi:10.1126/sciadv.adx9221

BibTeX
@article{Liu2025,
  author = {Liu, Guolong and Tian, Xiaoling and Wang, Qiudao and Xu, Saijuan and Jiang, Yanhong and Gao, Ying and Wu, Yuxuan},
  title = {Prdm12 governs an epigenetic checkpoint linking neuroimmune cross-talk to CD8 + T cell exhaustion-suppressed antitumor immunity},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {33},
  doi = {10.1126/sciadv.adx9221}
}
Kostenlos starten →